^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Gastroesophageal Junction Adenocarcinoma |
| Drug: | Cyramza (ramucirumab) (VEGFR-2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
12/19/2014
Excerpt:
Cyramza monotherapy is indicated for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy, for whom treatment in combination with paclitaxel is not appropriate.
Source:
Published date:
12/19/2014
Excerpt:
Cyramza in combination with paclitaxel is indicated for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy.
Secondary therapy:
paclitaxel
Source:
Published date:
04/21/2014
Excerpt:
CYRAMZA® is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated:…as a single agent...for treatment of advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy.
Source:
Published date:
04/21/2014
Excerpt:
CYRAMZA® is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated:…in combination with paclitaxel, for treatment of advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy.
Secondary therapy:
paclitaxel
Source:
Published date:
01/05/2023
Excerpt:
For patients with advanced gastroesophageal or GEJ AC whose disease has progressed after first-line therapy, ramucirumab plus paclitaxel is recommended.
Secondary therapy:
paclitaxel
DOI:
10.1200/JCO.22.02331
Source:
Excerpt:
...the guidelines have included the targeted therapy ramucirumab (category 1 for EGJ adenocarcinoma; category 2A for esophageal adenocarcinoma) as a single agent or in combination with paclitaxel (preferred) as treatment options for second line or subsequent therapy...Esophageal and Esophagogastric Junction cancers: Other recommended regimens…Irinotecan and ramucirumab for adenocarcinoma…Fluorouracil and irinotecan + ramucirumab for adenocarcinoma...
Secondary therapy:
paclitaxel; 5-fluorouracil + irinotecan; irinotecan
Source:
Excerpt:
...the guidelines have included the targeted therapy ramucirumab (category 1 for EGJ adenocarcinoma; category 2A for esophageal adenocarcinoma) as a single agent...
Source:
Title:
Exploratory Analysis of Patients With Gastric/Gastroesophageal Junction Adenocarcinoma With or Without Liver Metastasis From the Phase 3 RAINBOW Study
Published date:
03/09/2023
Excerpt:
The presence of LM was associated with earlier progression than those without LM, particularly in patients receiving PL+PAC (hazard ratio [HR], 1.68). RAM+PAC treatment improved OS and PFS irrespective of LM status but showed greater improvement in LM+ than that in LM- (OS HR, 0.71 [LM+] vs. 0.88 [LM-]; PFS HR, 0.47 [LM+] vs. 0.76 [LM-])...Therefore, RAM+PAC is a clinically meaningful therapeutic option for patients with mGEA and LM.
Secondary therapy:
paclitaxel
DOI:
10.5230/jgc.2023.23.e15
Trial ID:
Source:
Title:
Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial
Published date:
10/06/2021
Excerpt:
Median progression-free survival was 4·14 months (95% CI 3·71–4·30) in the ramucirumab plus paclitaxel group compared with 3·15 months (2·83–4·14) in the placebo plus paclitaxel group (hazard ratio [HR] 0·765, 95% CI 0·613–0·955, p=0·0184)….These findings, along with the results from RAINBOW, support the use of ramucirumab plus paclitaxel as second-line therapy in a predominantly Chinese population with advanced gastric or GEJ adenocarcinoma.
Secondary therapy:
paclitaxel
DOI:
https://doi.org/10.1016/S2468-1253(21)00313-7
Trial ID:
Source:
Title:
RAINBOW-Asia: A randomized, multicenter, double-blind, phase III study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line chemotherapy with platinum and fluoropyrimidine.
Published date:
01/22/2021
Excerpt:
The combination of RAM+PTX as 2nd-line therapy demonstrated a statistically significant PFS benefit, and OS benefit consistent with RAINBOW study in a predominantly Chinese population with advanced gastric and GEJ cancer.
Secondary therapy:
paclitaxel
DOI:
10.1200/JCO.2021.39.3_suppl.199
Trial ID:
Source:
Title:
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
Published date:
09/17/2014
Excerpt:
This randomised, placebo-controlled, double-blind, phase 3 trial was done at 170 centres in 27 countries in North and South America, Europe, Asia, and Australia. Patients aged 18 years or older with advanced gastric or gastro-oesophageal junction adenocarcinoma...665 patients were randomly assigned to treatment—330 to ramucirumab plus paclitaxel and 335 to placebo plus paclitaxel. Overall survival was significantly longer in the ramucirumab plus paclitaxel group than in the placebo plus paclitaxel group (median 9·6 months [95% CI 8·5–10·8] vs 7·4 months [95% CI 6·3–8·4], hazard ratio 0·807 [95% CI 0·678–0·962]; p=0·017).
Secondary therapy:
paclitaxel
DOI:
10.1016/S1470-2045(14)70420-6
Trial ID:
